Endothelial NADPH oxidase 4 mediates vascular endothelial growth factor receptor 2-induced intravitreal neovascularization in a rat model of retinopathy of prematurity

Molecular Vision

Volumn 20, Issue , 2014, Pages 231-241

  Wang, Haibo ^a   Yang, Zhihong ^a   Jiang, Yanchao ^a   Hartnett, M Elizabeth ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICHLORODIHYDROFLUORESCEIN DIACETATE; LECTIN; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SMALL INTERFERING RNA; STAT3 PROTEIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LABELING; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME INDUCTION; FLUORESCENCE ANALYSIS; INTRAVITREAL NEOVASCULARIZATION; NEOVASCULARIZATION (PATHOLOGY); NEWBORN; NONHUMAN; OXYGEN CONCENTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; RETINA CELL; RETROLENTAL FIBROPLASIA; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GENE KNOCKDOWN TECHNIQUES; HUMANS; NADPH OXIDASE; OXYGEN; PHOSPHORYLATION; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RETINA; RETINOPATHY OF PREMATURITY; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VITREOUS BODY;

EID: 84896826170     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Ushio-Fukai M. Redox signaling in angiogenesis: Role of NADPH oxidase. Cardiovasc Res 2006; 71:226-35. [PMID: 16781692.
2. Wilkinson-Berka JL, Rana I, Armani R, Agrotis A. Reactive oxygen species, Nox and angiotensin II in angiogenesis: implications for retinopathy. Clin Sci (Lond) 2013; 124:597-615. [PMID: 23379642].
3. Ushio-Fukai M, Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett 2008; 266:37-52. [PMID: 18406051.
4. Krause KH. Tissue distribution and putative physiological function of NOX family NADPH oxidases. Jpn J Infect Dis 2004; 57:S28-9. [PMID: 15507765.
5. Pendyala S, Gorshkova IA, Usatyuk PV, He D, Pennathur A, Lambeth JD, Thannickal VJ, Natarajan V. Role of Nox4 and Nox2 in hyperoxia-induced reactive oxygen species generation and migration of human lung endothelial cells. Antioxid Redox Signal 2009; 11:747-64. [PMID: 18783311.
6. Garrido-Urbani S, Jemelin S, Deffert C, Carnesecchi S, Basset O, Szyndralewiez C, Heitz F, Page P, Montet X, Michalik L, Arbiser J, Rüegg C, Krause KH, Imhof BA. Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARalpha mediated mechanism. PLoS ONE 2011; 6:e14665-[PMID: 21326871].
7. Wilkinson-Berka JL, Deliyanti D, Rana I, Miller AG, Agrotis A, Armani R, Szyndralewiez C, Wingler K, Touyz RM, Cooper ME, Jandeleit-Dahm KA, Schmidt HH. NADPH oxidase, NOX1, mediates vascular injury in ischemic retinopathy. Antioxid Redox Signal 2013; [PMID: 24053718.
8. Saito Y, Geisen P, Uppal A, Hartnett ME. Inhibition of NAD(P)H oxidase reduces apoptosis and avascular retina in an animal model of retinopathy of prematurity. Mol Vis 2007; 13:840-53. [PMID: 17615545.
9. Al-Shabrawey M, Bartoli M, El Remessy AB, Ma G, Matragoon S, Lemtalsi T, Caldwell RW, Caldwell RB. Role of NADPH Oxidase and Stat3 in Statin-Mediated Protection against Diabetic Retinopathy. Invest Ophthalmol Vis Sci 2008; 49:3231-8. [PMID: 18378570.
10. Li J, Wang JJ, Yu Q, Chen K, Mahadev K, Zhang SX. Inhibition of reactive oxygen species by Lovastatin downregulates vascular endothelial growth factor expression and ameliorates blood-retinal barrier breakdown in db/db mice: role of NADPH oxidase 4. Diabetes 2010; 59:1528-38. [PMID: 20332345.
11. Kushner EJ, Bautch VL. Building blood vessels in development and disease. Curr Opin Hematol 2013; 20:231-6. [PMID: 23567339.
12. Smith LEH, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, D'Amore PA. Oxygen induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994; 35:101-11. [PMID: 7507904.
13. Penn JS, Tolman BL, Lowery LA. Variable oxygen expo sure causes preretinal neovascularisation in the newborn rat. Invest Ophthalmol Vis Sci 1993; 34:576-85. [PMID: 8449677.
14. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF. Nat Med 2003; 9:677-84. [PMID: 12778166.
15. Caprara C, Grimm C. From oxygen to erythropoietin: Relevance of hypoxia for retinal development, health and disease. Prog Retin Eye Res 2012; 31:89-119. [PMID: 22108059.
16. Chen J, Connor KM, Aderman CM, Willett KL, Aspegren OP, Smith LEH. Suppression of Retinal Neovascularization by Erythropoietin siRNA in a Mouse Model of Proliferative Retinopathy. Invest Ophthalmol Vis Sci 2009; 50:1329-35. [PMID: 18952918.
17. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LEH. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995; 92:905-9. [PMID: 7846076.
18. Cao Y, Linden P, Shima D, Browne F, Folkman J. In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. J Clin Invest 1996; 98:2507-11. [PMID: 8958213.
19. Tawfik A, Sanders T, Kahook K, Akeel S, Elmarakby A, Al Shabrawey M. Suppression of Retinal Peroxisome Proliferator-Activated Receptor {gamma} in Experimental Diabetes and Oxygen-Induced Retinopathy: Role of NADPH Oxidase. Invest Ophthalmol Vis Sci 2009; 50:878-84. [PMID: 18806296].
20. Capozzi ME, McCollum GW, Savage SR, Penn JS. Peroxisome Proliferator-Activated Receptor-beta/delta Regulates Angiogenic Cell Behaviors and Oxygen-Induced Retinopathy. Invest Ophthalmol Vis Sci 2013; 54:4197-207. [PMID: 23716627].
21. Wilkinson-Berka JL, Alousis NS, Kelly DJ, Gilbert RE. COX-2 Inhibition and Retinal Angiogenesis in a Mouse Model of Retinopathy of Prematurity. Invest Ophthalmol Vis Sci 2003; 44:974-9. [PMID: 12601017.
22. Nagai N, Noda K, Urano T, Kubota Y, Shinoda H, Koto T, Shinoda K, Inoue M, Shiomi T, Ikeda E, Tsubota K, Suda T, Oike Y, Ishida S. Selective suppression of pathologic, but not physiologic, retinal neovascularization by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci 2005; 46:1078-84. [PMID: 15728568.
23. Saito Y, Uppal A, Byfield G, Budd S, Hartnett ME. Activated NAD(P)H Oxidase from Supplemental Oxygen Induces Neovascularization Independent of VEGF in Retinopathy of Prematurity Model. Invest Ophthalmol Vis Sci 2008; 49:1591-8. [PMID: 18385079.
24. Byfield G, Budd S, Hartnett ME. The role of supplemental oxygen and JAK/STAT signaling in intravitreous neovascularization in a ROP rat model. Invest Ophthalmol Vis Sci 2009; 50:3360-5. [PMID: 19264880.
25. Al-Shabrawey M, Bartoli M, El Remessy AB, Platt DH, Matragoon S, Behzadian MA, Caldwell RW, Caldwell RB. Inhibition of NAD(P)H Oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. Am J Pathol 2005; 167:599-607. [PMID: 16049343.
26. Al-Shabrawey M, Rojas M, Sanders T, Behzadian A, El-Remessy A, Bartoli M, Parpia AK, Liou G, Caldwell RB. Role of NADPH oxidase in retinal vascular inflamma tion. Invest Ophthalmol Vis Sci 2008; 49:3239-44. [PMID: 18378574.
27. Dvoriantchikova G, Grant J, Santos AR, Hernandez E, Ivanov D. Neuronal NAD(P)H oxidases contribute to ROS production and mediate RGC death after ischemia. Invest Ophthalmol Vis Sci 2012; 53:2823-30. [PMID: 22467573.
28. Schröder K, Zhang M, Benkhoff S, Mieth A, Pliquett R, Kosowski J, Kruse C, Luedike P, Michaelis UR, Weissmann N, Dimmeler S, Shah AM, Brandes RP. Nox4 Is a Protective Reactive Oxygen Species Generating Vascular NADPH Oxidase/Novelty and Significance. Circ Res 2012; 110:1217-25. [PMID: 22456182.
29. Maile LA, Gollahon K, Wai C, Byfield G, Hartnett ME, Clemmons D. Disruption of the association of integrin-associated protein (IAP) with tyrosine phosphatase non-receptor type substrate-1 (SHPS)-1 inhibits pathophysiological changes in retinal endothelial function in a rat model of diabetes. Diabetologia 2012; 55:835-44. [PMID: 22193512.
30. Hartnett ME, Penn JS. Mechanisms and Management of Retinopathy of Prematurity. N Engl J Med 2012; 367:2515-26. [PMID: 23268666.
31. Penn JS, Henry MM, Tolman BL. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res 1994; 36:724-31. [PMID: 7898981.
32. Wang H, Geisen P, Wittchen ES, King B, Burridge K, D'Amore PA, Hartnett ME. The Role of RPE Cell-Associated VEGF189 in Choroidal Endothelial Cell Transmigration across the RPE. Invest Ophthalmol Vis Sci 2011; 52:570-8. [PMID: 20811045.
33. McCloskey M, Wang H, Jiang Y, Smith GW, Strange J, Hartnett ME. Anti-VEGF Antibody Leads to Later Atypical Intravitreous Neovascularization and Activation of Angiogenic Pathways in a Rat Model of Retinopathy of Prematurity. Invest Ophthalmol Vis Sci 2013; 54:2020-6. [PMID: 23449716.
34. Budd SJ, Thompson H, Hartnett ME. Association of Retinal Vascular Endothelial Growth Factor With Avascular Retina in a Rat Model of Retinopathy of Prematurity. Arch Ophthalmol 2010; 128:1014-21. [PMID: 20697002.
35. Monaghan-Benson E, Hartmann J, Vendrov AE, Budd S, Byfield G, Parker A, Ahmad F, Huang W, Runge M, Burridge K, Madamanchi N, Hartnett ME. The Role of Vascular Endothelial Growth Factor-Induced Activation of NADPH Oxidase in Choroidal Endothelial Cells and Choroidal Neovascularization. Am J Pathol 2010; 177:2091-102. [PMID: 20802176.
36. Geisen P, Peterson L, Martiniuk D, Uppal A, Saito Y, Hartnett M. Neutralizing antibody to VEGF reduces intravitreous neovascularization and does not interfere with vascularization of avascular retina in an ROP model. Mol Vis 2008; 14:345-57. [PMID: 18334951.
37. Budd S, Byfield G, Martiniuk D, Geisen P, Hartnett ME. Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROP. Exp Eye Res 2009; 89:718-27. [PMID: 19576214.
38. Saint-Geniez M, Maldonado AE, D'Amore PA. VEGF Expression and Receptor Activation in the Choroid during Development and in the Adult. Invest Ophthalmol Vis Sci 2006; 47:3135-42. [PMID: 16799060.
39. Bautch VL. VEGF-directed blood vessel patterning: from cells to organism. Cold Spring Harbor 2012.
40. Dvorak HF. Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy. J Clin Oncol 2002; 20:4368-80. [PMID: 12409337.
41. Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, New T, O'Toole K, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Yamashiro DJ, Kandel JJ. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proceedings of the National Academy of Sciences 2003:143, 2908100.
42. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331:1480-7. [PMID: 7526212.
43. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LEH. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995; 92:10457-61. [PMID: 7479819.
44. Ng EWM, Adamis AP. Anti-VEGF Aptamer (Pegaptanib) Therapy for Ocular Vascular Diseases. Ann N Y Acad Sci 2006; 1082:151-71. [PMID: 17145936.
45. Kami J, Muranaka K, Yanagi Y, Obata R, Tamaki Y, Shibuya M. Inhibition of choroidal neovascularization by blocking vascular endothelial growth factor receptor tyrosine kinase. Jpn J Ophthalmol 2008; 52:91-8. [PMID: 18626731.
46. Bird AC. Therapeutic targets in age-related macular disease. J Clin Invest 2010; 120:3033-41. [PMID: 20811159.
47. Nicholson BP, Schachat A. A review of clinical trials of antiVEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010; 248:915-30. [PMID: 20174816.
48. Raizada S, Al Kandari J, Al Sabti K. Will the BEAT-ROP Study Results Really Beat ROP? Invest Ophthalmol Vis Sci 2011; 52:9288-9. [PMID: 22127432.
49. Mititelu M, Chaudhary KM, Lieberman RM. An Evidence Based Meta-analysis of Vascular Endothelial Growth Factor Inhibition in Pediatric Retinal Diseases: Part 1. Retinopathy of Prematurity. J Pediatr Ophthalmol Strabismus 2012; 49:332-40. [PMID: 22938516.
50. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON: A Multicenter Cohort Study (SEVEN-UP). Ophthalmology 2013; 120:2292-9. [PMID: 23642856.
51. Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, Kusaka S. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 2012; 153:327-33. [PMID: 21930258.
52. Sun Y, Jin K, Xie L, Childs J, Mao XO, Logvinova A, Greenberg DA. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 2003; 111:1843-[PMID: 12813020].
53. Chu H, Tang Y, Dong Q. Protection of Vascular Endothelial Growth Factor to Brain Edema Following Intracerebral Hemorrhage and Its Involved Mechanisms: Effect of Aquaporin-4. PLoS ONE 2013; 8:e66051-[PMID: 23805198].
54. Hartnett ME, Martiniuk D, Byfield G, Geisen P, Zeng G, Bautch VL. Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in a rat model of ROP: relevance to plus disease. Invest Ophthalmol Vis Sci 2008; 49:3107-14. [PMID: 18378573.